MANKIND PHARMA share price has plunged 3% and is presently trading at Rs 2,409.1.
Meanwhile, the BSE HEALTHCARE index is at 42,972.8 (down 0.5%).
Among the top losers in the BSE HEALTHCARE index today are GRANULES INDIA (down 4.5%) and Dr. Reddys (down 2.7%).
Pfizer (up 4.3%) and MAX HEALTHCARE INSTITUTE (up 1.9%) are among the top gainers today.
Over the last one year, MANKIND PHARMA has moved up from Rs 1,783.0 to Rs 2,409.1, registering a gain of Rs 626.2 (up 35.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,815.8 to 42,972.8, registering a gain of 54.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 127.2%), Glenmark Pharma (up 123.8%) and SUVEN PHARMACEUTICALS (up 115.5%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 82,507.0 (up 0.2%).
The top gainers among the BSE Sensex today are Bajaj Finserv (up 3.5%) and HCl Tech. (up 3.2%). The most traded stocks in the BSE Sensex are Tata Steel and SBI.
In the meantime, NSE Nifty is at 25,258.6 (up 0.1%). Bajaj Finserv and Bajaj Finance are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,075.8 to 82,507.0, registering a gain of 17,431.2 points (up 26.8%).
MANKIND PHARMA net profit grew 10.2% YoY to Rs 5,392 million for the quarter ended June 2024, compared to a profit of Rs 4,895 million a year ago. Net sales rose 12.2% to Rs 28,934 million during the period as against Rs 25,786 million in April-June 2023.
For the year ended March 2024, MANKIND PHARMA reported 48.3% increase in net profit to Rs 19,418 million compared to net profit of Rs 13,097 million during FY23. Revenue of the company grew 18.1% to Rs 103,348 million during FY24.
The current Price to earnings ratio of MANKIND PHARMA, based on rolling 12 month earnings, stands at 48.8.
Equitymaster requests your view! Post a comment on "MANKIND PHARMA Plunges 3%; BSE HEALTHCARE Index Down 0.5%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!